To be clear: Our knowledge regarding hydroxychloroquine is preliminary, and more study is urgently needed. Nor can we forget that numerous other potential treatments are now the subject of urgent consideration, any of which could prove to be a breakthrough, either alone or in combination with each other.
But the FDA’s emergency authorization is based on data showing therapeutic and potential prophylactic effects. And it’s being studied right now at leading medical facilities here in New York and around the world. Clinical trials are ongoing, and we’re learning more every day about the potential of this treatment and the best way to apply it.
Supply concerns, while justified, are being addressed. We must ensure that people living with the chronic illnesses treated by these medicines — such as lupus and rheumatoid arthritis — can continue to access them without interruption.